Side-by-side comparison
AbbVie vs Bristol-Myers Squibb
As of Sep 25, 2026, P/E is 74.7x for AbbVie vs 13.8x for Bristol-Myers Squibb; P/S is 7.3x for AbbVie vs 2.6x for Bristol-Myers Squibb; revenue growth is 10.4% for AbbVie vs 3.1% for Bristol-Myers Squibb; net margin is 9.8% for AbbVie vs 18.9% for Bristol-Myers Squibb.
Key metrics
| Metric | ABBV | BMY |
|---|---|---|
| Price | $264.34 | $62.86 |
| Market cap | $467.12B | $128.41B |
| P/E | 74.7x (#2) | 13.8x (#1) |
| P/S | 7.3x (#2) | 2.6x (#1) |
| Revenue growth | 10.4% (#1) | 3.1% (#2) |
| Operating margin | 26.2% (#1) | — |
| Net margin | 9.8% (#2) | 18.9% (#1) |
| Debt / equity | — | 1.89 (#1) |
| 1-year return | +19.8% (#2) | +42.5% (#1) |
| Research score | 55/100 (#2) | 71/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- AbbVie Inc. (ABBV) — Drug Manufacturers—General
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General